medRxivGenetic & Genomic MedicinePreprint
Truncated ASXL3 Alters Chromatin Accessibility and Epigenetic Landscape in Bainbridge-Ropers Syndrome Suggesting a Gain-of-Function Etiology
Nofar MoriD, Inna Shomer, Shaul Raviv, Noga Budick-HarmeliniD, Tanya Matzevitch, Shalhevet Azriel, Joseph G. GleesoniD, Yoach RaisiD, Rebecca HaffneriD, Shifra Ben‐DoriD, Omri NayshooliD, Sharon Avkin-Nachum, Adi Yahalom, Efrat Glick‐Saar, Gali HeimeriD, Gidi Rechavi, Dan DominissiniiD
Abstract
Bainbridge-Ropers syndrome (BRS) is a rare neurodevelopmental disorder caused by truncating mutations in the epigenetic regulator ASXL3. While traditionally considered a haploinsufficiency disorder, the precise molecular mechanisms driving BRS remain poorly understood. Here, we combine patient-derived cellular lines and novel mouse models to elucidate the molecular function of disease-associated ASXL3 variants. We show that several pathogenic ASXL3 variants escape nonsense-mediated decay (NMD), possibly leading to the accumulation of truncated protein, and widespread epigenetic changes, resulting in distinct transcriptomic and proteomic profiles. These changes include increased chromatin accessibility and global DNA hypomethylation, particularly at promoters and imprinted loci. A knock-in Asxl3 mouse model harboring a mutation corresponding to one diagnosed in BRS-patient recapitulated the molecular features BRS-patient derived cellular model, including the escape from NMD and Polycomb Repressive Complex 2 (PRC2)-related transcriptomic dysregulation. In contrast, heterozygous Asxl3 knockout mice and transient knockdown models showed no phenotype, indicating that truncated ASXL3 that may exert dominant-negative effects rather than simple loss of function. This molecular dissection offers new venues for treatment, including allele-specific Antisense Oligonucleotides (ASO), which were used by us in patient-derived cells to downregulate the expression of the mutated allele, and were able to induce partial recovery of the proteomic profile. Taken together, our results support a dominant-negative mechanism for BRS causing truncating mutations, offering a compelling rationale for allele-specific ASO therapeutic strategy. One sentence SummaryPatient-derived neuronal models and mouse models reveal that truncated ASXL3 drive epigenetic dysregulation through a gain-of-function mechanism.
- organism: human
- organism: mouse
- assay: DNA methylation
- assay: proteomics
- research focus: cell type annotation
- research focus: differential expression
- approach: experimental assay
- Citations
- 0
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- ASXL3 truncating patient variants mediate transcriptional gain-of-function and are antisense oligonucleotide-responsive
Yuji Nakamura, Toan Nguyen, … Joseph G. Gleeson·medRxiv·Jul 22, 2026
- Truncating ASXL1 variants rewire cellular metabolism via mitochondrial pyruvate carrier repression
Isabella Lin, Michael Sigfrid S. Reyes, … Valerie A. Arboleda·bioRxiv·Jul 17, 2026
- Oncogenic truncations of ASXL1 enhance a motif for BRD4 ET-domain binding
A. E. Burgess, T. Kleffmann, P. D. Mace·bioRxiv·Jul 15, 2021
- Truncating ASXL1 mutations in Bohring-Opitz Syndrome dysregulate canonical and non-canonical Wnt Signaling
Isabella Lin, Angela Wei, … Valerie A. Arboleda·bioRxiv·Dec 15, 2022
- An ASXL3-thyroid hormone axis in parvalbumin interneurons controls autism-like behaviors
Chaodong Ding, Yiting Yuan, … Zilong Qiu·Science AdvancesPeer-reviewed·Sep 23, 2026
- A novel iPSC model of Bryant-Li-Bhoj neurodevelopmental/neurodegenerative syndrome demonstrates the role of histone H3.3 in chromatin dynamics, neuronal differentiation, and maturation
Annabel K. Sangree, Rajesh Angireddy, … Elizabeth J. K. Bhoj·Journal of Translational MedicinePeer-reviewed·Feb 13, 2026